We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

HospiMedica

Download Mobile App
Recent News Medica 2024 AI Critical Care Surgical Techniques Patient Care Health IT Point of Care Business Focus

New Technologies Fuel EU Diagnostics Market

By HospiMedica staff writers
Posted on 04 Oct 2005
Sparked by new technologies and other medical advances, the European in vitro diagnostics (IVD) market is expected to reach U.S.$43 billion in 2011, up from $28.7 billion in 2004, according to a new report from Frost & Sullivan (Palo Alto, CA, USA), an international consulting firm.

The expanding aged population and molecular diagnostics will also help boost the IVD market, although cost containment and changing economic conditions worldwide are hindering the uptake of IVD technologies. This is particularly true in developing nations in Asia, Latin America, and Africa, where poor healthcare infrastructures and struggling economies impede modernization and create environments that are extremely price sensitive. Distribution, local suppliers, and minimal expenditures for healthcare also create hurdles to market growth.

Recently, healthcare awareness programs and government initiatives to increase spending have stimulated improvements in European countries, creating opportunities for future growth. As markets become more competitive and consumers raise demands, low prices, multiple tests on a single platform, and customer service gain importance. Understanding specific markets and clinical needs is increasingly important to promote adoption of new technologies, according to Silvia Cerqueira, an analyst with Frost & Sullivan. "New IVD systems must also address unmet needs and provide substantial added value.” Smaller companies can combat regulatory challenges by collaborating with larger companies and benefiting from their experience and economic resources.

Discoveries and innovations in molecular diagnostics are propelling the advancement of personalized medicine and creating new growth opportunities for IVDs. As manufacturers concentrate on providing greater benefits such as early diagnosis, improved decision-making, and better monitoring of treatment, the market will maintain its strong growth trajectory. Rising insurance coverage in such countries as France, Spain, and Germany will also contribute to positive trends in the market.




Related Links:
Frost & Sullivan

Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
New
Cannulating Sphincterotome
TRUEtome
New
Documentation System For Blood Banks
HettInfo II

Latest Business News

Boston Scientific Acquires Medical Device Company Intera Oncology

MEDICA 2024 to Highlight Hot Topics of MedTech Industry

Start-Ups To Once Again Play Starring Role at MEDICA 2024